NCT01747278

Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients

The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD) treated with high-dose glucocorticoids and immunosuppressive agents. Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12 weeks.

Conditions

• Pneumonia, Pneumocystis
• Prevention & Control

Interventions

Type	Name	Description
DRUG	Trimethoprim/Sulfamethoxazole	Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.

Timeline

• Start date: 2012-08-01
• Primary completion: 2013-06-01
• Completion: 2013-08-01
• First posted: 2012-12-11
• Last updated: 2012-12-11

Locations

1 site across 1 country: China